Chief Executive Officer
Joe Victor serves on the Board of Directors at Rarecyte and has been a Venture Partner with 5AM Ventures since 2016. Prior to his joining 5AM Ventures, Mr. Victor served as CEO of Startide Sciences, a 5AM Ventures portfolio company chartered to identify and develop innovative technologies in the Life Sciences research tools markets. Prior to Startide, Mr. Victor served as CEO of DVS Sciences (acquired by Fluidigm Inc.), and Applied Precision Inc (acquired by GE Healthcare). He currently serves as Executive Chairman on the boards of Biodesy and Purigen Biosystems as well as on the Boards of RareCyte, Precision Nanosystems, and Glencoe Software. Mr. Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation. Mr. Victor has also held various executive management and technical positions in the high technology, aviation, and energy markets. Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington.
Chief Technology Officer
Ron brings a wealth of corporate leadership and technical experience to RareCyte. Prior to founding RareCyte, he was a founder and CEO at Applied Precision, Inc. (API). API initially specialized in semi-conductors. The company eventually spun off this division and began creating innovative imaging solutions for life sciences. Ron was instrumental in launching the popular DeltaVision line of microscopes, including the DeltaVision Elite and DeltaVision OMX, one of the first super-resolution imaging systems on the market. The company was sold to GE Life Sciences in 2011. His professional experience spans decades and he holds several patents.
Eric Kaldjian MD
Chief Medical Officer
Eric earned his MD and trained in pathology at the University of Michigan. He was a research fellow at the National Cancer Institute and is certified by the American Board of Pathology. Before RareCyte he was the Medical Director of Companion Diagnostics at Ventana Medical Systems/Roche Tissue Diagnostics. Eric’s pharmaceutical experience has included discovery research, toxicology, and exploratory and late phase clinical development at Hoffmann-La Roche and Parke-Davis / Pfizer. He was a director of clinical genomics at Gene Logic and Chief Scientific Officer at Transgenomic. He has degree in chemistry from Harvard and studied music at Trinity College, Cambridge, England.
Tad George, Ph.D.
Senior VP, Bio R&D
Tad has over 15 years of startup experience dedicated to creating scientific markets for novel instrumentation platforms that span basic research, drug discovery and clinical applications. Prior to joining RareCyte, Tad has held similar positions at Biodesy, Inc. and DVS Sciences, and was Director of Biology at Amnis Corporation. Tad completed his B.A. in Biochemistry from the Univ. of Texas at Austin, Ph.D. in Immunology from UT Southwestern Medical Center at Dallas, and post-doctoral training at Immunex Corp. in Seattle.
Senior VP, Engineering
Steve Reese comes to Rarecyte from his previous role as Principal Systems Engineer within the Genomics and Cellular Research division of GE Life Sciences. He has been involved with guiding the development of more than 20 automated fluorescent imaging systems during his 25 years with Applied Precision and GE. Yale trained as an Electrical Engineer, he has focused his attention on how to optimize system design and lead teams from problem definition through invention, design, and product execution.
Senior VP, Sales and Marketing
Bryan Sullivan is a Sales Executive with 33 years of experience in developing strategic business relationships, building and leading sales and marketing organizations most recently as a Global Business Director at GE Life Sciences. Prior to his time as Global Business Director, Bryan held various sales leadership roles at GE Life Sciences, Applied Precision, Siemens Medical and Baxter Healthcare. He earned his bachelor’s degree from Fordham University and his MBA from Pepperdine University.
VP, Operations and Quality
Tony has over 18 years of experience within Operations and is responsible for Quality, Supply Chain, Materials, and Manufacturing at RareCyte. He brings a wealth of diverse experience from holding roles of increasing responsibility at Chrysler, Raytheon, Ingersoll Rand, and most recently Verathon Inc. where he led Operations for two FDA regulated manufacturing sites (US and Canada) producing Class I and Class II medical devices. He holds a B.S. degree in Mechanical Engineering from Purdue University and is a certified Lean and Six Sigma Expert.
Kelly Gordon, Ph.D., MB (ASCP)
VP, CDx Clinical and Regulatory Affairs
Kelly has deep experience in all regulatory aspects for in vitro diagnostics and companion diagnostics. Kelly will be creating and implementing RareCyte’s regulatory strategy for all companion diagnostic programs. Kelly was formally trained in pharmacology with hands-on experience in biobanking, biomarker discovery, cancer research, clinical testing, clinical trial operations, companion and complementary diagnostics, laboratory management, and regulatory/clinical strategy. Kelly’s most recent positions were Director, Translational Medicine at Loxo Oncology; Director, HTG Molecular Diagnostics; VP Development, Provista Diagnostics; and CDx Regulatory Affairs Manager at Roche/Ventana. Kelly completed her B.S. in Molecular and Cellular Biology from the Univ. of Arizona, Ph.D. in Pharmacology from Duke University, and Postdoctoral training at the Cancer Biology Translational Genomics Research Institute and Arizona Cancer Center.
VP, Business Development
Leighton has over 30 years of experience in developing, launching and commercializing new technology platforms for global markets. His technical and management career focused on the pioneer instrumentation and assays for High Throughput Screening, High Content Screening and highly multiplexed imaging to support pharmaceutical drug discover/development and diagnostics. With an extensive career at GE Healthcare in Life Sciences and Diagnostic business units, Leighton held leadership positions in R&D, Operations and Commercial organizations, additionally leading the acquisition and integration of several high-performance imaging companies. Most recently, Leighton was the Director of Operations, Pharma Services at NeoGenomics. Leighton holds a bachelor’s degree in biological sciences from the University of West England, Bristol.